Evidence map›Paper›PMID 32231245›Full record

ArticleProstate cancer and prostatic diseases2020

Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier.

Jeffrey J Tosoian, Samuel R Birer, R Jeffrey Karnes, Jingbin Zhang, Elai Davicioni, Eric E Klein, Stephen J Freedland, Sheila Weinmann, Bruce J Trock, Robert T Dess and 17 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 14 institutions in 2 countries.

Jeffrey J TosoianDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Samuel R BirerDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
R Jeffrey KarnesDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Jingbin ZhangDecipher Biosciences, Vancouver, BC, Canada.
Elai DavicioniDecipher Biosciences, Vancouver, BC, Canada.
Eric E KleinGlickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-1783-0698
Stephen J FreedlandDepartment of Urology, Cedars-Sinai, Los Angeles, CA, USA.
Sheila WeinmannCenter for Health Research, Kaiser Permanente, Portland, OR, USA.
Bruce J TrockDepartment of Urology, Johns Hopkins, Baltimore, MD, USA.
Robert T DessDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0003-2331-3758
Shuang G ZhaoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
William C JacksonDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Kosj YamoahDepartment of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Alan Dal PraDepartment of Radiation Oncology, University of Miami, Miami, FL, USA.
Brandon A MahalDepartment of Radiation Oncology, Brigham Women's Hospital, Boston, MA, USA.
Todd M MorganDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-1140-0603
Rohit MehraDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-6955-8884
Samuel KaffenbergerDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Simpa S SalamiDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Christopher KaneDepartment of Urology, University of California San Diego, San Diego, CA, USA.
Alan PollackDepartment of Radiation Oncology, University of Miami, Miami, FL, USA.
Robert B DenDepartment of Radiation Oncology, Thomas Jefferson, Philadelphia, PA, USA.
Alejandro BerlinDepartment of Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-1880-6905
Edward M SchaefferDepartment of Urology and Polsky Urologic Cancer Institute, Northwestern University, Chicago, IL, USA.
Paul L NguyenDepartment of Radiation Oncology, Brigham Women's Hospital, Boston, MA, USA.
Felix Y FengDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Daniel E SprattDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. sprattda@med.umich.edu.ORCID http://orcid.org/0000-0002-5973-4741
University of Michigan · USBrigham and Women's Hospital · USDecipher Biosciences (Canada) · CAUniversity of Miami · USCedars-Sinai Medical Center · USCleveland Clinic · USJohns Hopkins University · USKaiser Permanente Center for Health Research · USMayo Clinic in Arizona · USMoffitt Cancer Center · USNorthwestern University · USPrincess Margaret Cancer Centre · CAUniversity of California San Diego · USUniversity of California, San Francisco · US

Funding

Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Timothy Dess · 2014 to 2026
$27.6M
Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
NCI NIH HHS P50 CA186786NCI NIH HHS P50CA186786NCI NIH HHS T32 CA180984
6 · The paper itself

Abstract

backgroundProstate cancer exhibits biological and clinical heterogeneity even within established clinico-pathologic risk groups. The Decipher genomic classifier (GC) is a validated method to further risk-stratify disease in patients with prostate cancer, but its performance solely within National Comprehensive Cancer Network (NCCN) high-risk disease has not been undertaken to date.

methodsA multi-institutional retrospective study of 405 men with high-risk prostate cancer who underwent primary treatment with radical prostatectomy (RP) or radiation therapy (RT) with androgen-deprivation therapy (ADT) at 11 centers from 1995 to 2005 was performed. Cox proportional hazards models were used to determine the hazard ratios (HR) for the development of metastatic disease based on clinico-pathologic variables, risk groups, and GC score. The area under the receiver operating characteristic curve (AUC) was determined for regression models without and with the GC score.

resultsOver a median follow-up of 82 months, 104 patients (26%) developed metastatic disease. On univariable analysis, increasing GC score was significantly associated with metastatic disease ([HR]: 1.34 per 0.1 unit increase, 95% confidence interval [CI]: 1.19-1.50, p < 0.001), while age, serum PSA, biopsy GG, and clinical T-stage were not (all p > 0.05). On multivariable analysis, GC score (HR: 1.33 per 0.1 unit increase, 95% CI: 1.19-1.48, p < 0.001) and GC high-risk (vs low-risk, HR: 2.95, 95% CI: 1.79-4.87, p < 0.001) were significantly associated with metastasis. The addition of GC score to regression models based on NCCN risk group improved model AUC from 0.46 to 0.67, and CAPRA from 0.59 to 0.71.

conclusionsAmong men with high-risk prostate cancer, conventional clinico-pathologic data had poor discrimination to risk stratify development of metastatic disease. GC score was a significant and independent predictor of metastasis and may help identify men best suited for treatment intensification/de-escalation.

Indexed as

AgedBiomarkers, TumorCohort StudiesDisease ProgressionHumansKallikreinsMaleMiddle AgedModels, StatisticalNeoplasm MetastasisNomogramsPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesBiomarkers, TumorKallikreinsKLK3 protein, humanProstate-Specific Antigen

Identifiers

PMID32231245
PMCPMC10184170
OpenAlexW3013252558

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.